Wegovy 2.4 mg/0.75 mL pre-filled pen-injector

Wegovy 2.4 mg/0.75 mL pre-filled pen-injector

Wegovy® (semaglutide) is a prescription medication used for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia. It is a GLP-1 receptor agonist designed to help patients reduce their weight by decreasing appetite and improving insulin sensitivity. Wegovy should be used alongside a reduced-calorie diet and increased physical activity for effective long-term weight management.

The 2.4 mg/0.75 mL pre-filled pen-injector is the highest approved maintenance dose of Wegovy, designed for patients who have successfully completed the initial titration regimen. This pen provides the full, therapeutic dose after patients have gradually adjusted to the medication through lower doses of 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg.

How It Works:
Semaglutide, the active ingredient in Wegovy, mimics the action of GLP-1 (glucagon-like peptide-1), a hormone that plays a key role in regulating blood sugar and appetite. By stimulating the GLP-1 receptor, Wegovy helps the body increase insulin production when blood sugar levels are high, suppresses glucagon secretion, slows gastric emptying, and promotes feelings of fullness. These combined effects contribute to reduced food intake and weight loss.

Dosage and Administration:
Each pre-filled pen contains 2.4 mg of semaglutide in 0.75 mL of solution, delivered through a subcutaneous injection once a week. The injection can be administered in the abdomen, thigh, or upper arm. As with earlier doses, patients should rotate injection sites to minimize irritation and discomfort.

The 2.4 mg dose is typically used as the maintenance dose once the patient has progressed through the initial lower doses (0.25 mg, 0.5 mg, 1 mg, and 1.7 mg) as part of the titration schedule. This gradual increase helps reduce gastrointestinal side effects while ensuring maximum effectiveness in weight loss and blood sugar control.

Storage Instructions:
Before first use, Wegovy should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). After the first use, the pen can be kept at room temperature (up to 86°F or 30°C) for up to 28 days. Do not freeze the pen, and avoid exposing it to direct heat or sunlight.

Important Safety Information:
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not suitable for use in individuals with type 1 diabetes or diabetic ketoacidosis.

Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. Serious, though rare, side effects include pancreatitis, gallbladder disease, kidney problems, and increased heart rate. Regular monitoring is important to detect and address any potential complications.

Clinical Use:
The 2.4 mg dose is the maintenance dose for patients who have completed the initial titration regimen. This dose has been shown to be the most effective for achieving and maintaining significant weight loss. The gradual dose escalation minimizes side effects and improves patient adherence to the treatment plan.